Novo Nordisk UK (CPH:NOVO-B) has announced it is building up a four-month stock-pile in the event of a no-deal Brexit. The Danish company is taking this action in order to ensure patients’ insulin supply remains unaffected in the event of a no-deal Brexit.
The global pharmaceutical company founded in 1923 has its headquarters in Denmark. As a leading company in diabetes care, Novo Nordisk is Britain’s largest supplier of insulin. Moreover, the company employs roughly 43,100 people across 79 countries. Its products are marketed in more than 170 countries.
In addition to the increased stock supply, the company has already put in place a “robust” contingency plan. The decision to increase insulin stock builds upon Novo Nordisk’s no-deal Brexit program.
Corporate Vice President of Novo Nordisk UK, Pinder Sahota, has commented: “Our first commitment is to ensure that patients treated with our medicines remain unaffected in the event of a ‘no-deal’ Brexit.
“We are working closely with trade associations in the UK and the EU to ensure that the interests of our patients are at the forefront of negotiations.
Our decision to increase stock is in line with the technical notices and guidance published by the Government to industry.”
Fundamentally, Novo Nordisk is working with the Department of Health to guarantee continuity of supply, regardless of Brexit.
